Fig. 2: Clinical response in patients.
From: Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
A The swimmer’s plot showing clinical response of stringent complete response (sCR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD), relapse/progressive disease (PD), or death after BCMA CAR-T cell infusion, according to the International Myeloma Working Group consensus (2016). B Objective response rate (ORR, including PR, VGPR, and sCR) was analyzed based on two subgroups of plasma cells (<10% or ≥10%) in the bone marrow. C The curve shows progression-free survival (PFS) rates of 53.7% at 12 months and 31.8% at 18 months, respectively. Median PFS was 12.1 months. D CAR vector copies in each patient’s peripheral blood were assessed with quantitative PCR at different time points post infusion (left panel). The average copies at different time points were retro analyzed based on the two subgroups of clinical efficacy, sCR/VGPR, or PR/MR/SD (right panel). The sCR/VGPR subgroup shows earlier increased peak of copies.
